1
|
Varma A, Gemeda HB, McNulty MJ, McDonald KA, Nandi S, Knipe JM. Immobilization of transgenic plant cells towards bioprinting for production of a recombinant biodefense agent. Biotechnol J 2021; 16:e2100133. [PMID: 34347377 DOI: 10.1002/biot.202100133] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 07/23/2021] [Accepted: 07/27/2021] [Indexed: 11/08/2022]
Abstract
Transgenic rice cells (Oryza sativa) producing recombinant butyrylcholinesterase (BChE) as a prophylactic/therapeutic against organophosphate nerve agent poisoning, cocaine toxicity, and neurodegenerative diseases like Alzheimer's were immobilized in a polyethylene glycol-based hydrogel. The cells were sustained for 14 days in the semi-solid matrix, undergoing a growth phase from days 0-6, a BChE production phase in sugar-free medium from days 6-12, and a growth/recovery phase from days 12-14. Throughout this period, the cells maintained similar viability to those in suspension cultures and displayed analogous sugar consumption trends. The rice cells in the hydrogel also produced a significant amount of active BChE, comparable to the levels produced in liquid cultures. A considerable fraction of this BChE was secreted into the media, allowing for easier product separation. To the best of our knowledge, this proof-of-concept is the first report of immobilization of recombinant plant cells for continuous production of high-value heterologous proteins. This work serves as a foundation for further investigation towards plant cell bioprinting and the development of a simple, efficient, robust, modular, and potentially field-deployable bioreactor system for the manufacture of biologics. GRAPHICAL ABSTRACT AND LAY SUMMARY: Transgenic rice cells were combined with a polyethylene glycol tetra-acrylate (PEGTA) and lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) bioink and cured with UV light to construct an immobilized cell-based protein production system. The cells were maintained for 14 days in the hydrogel matrix and were induced to actively make and secrete recombinant butyrylcholinesterase, a complex enzyme that irreversibly binds to and can hydrolyze organophosphate. This proof-of-concept study showcases the use of immobilized and potentially bioprintable plant cells to produce high-value proteins with prophylactic and therapeutic applications.
Collapse
Affiliation(s)
- Anika Varma
- Department of Chemical Engineering, University of California, Davis, California, USA
| | - Hawi B Gemeda
- Lawrence Livermore National Laboratory, Livermore, California, USA
| | - Matthew J McNulty
- Department of Chemical Engineering, University of California, Davis, California, USA
| | - Karen A McDonald
- Department of Chemical Engineering, University of California, Davis, California, USA.,Global HealthShare Initiative, University of California, Davis, California, USA
| | - Somen Nandi
- Department of Chemical Engineering, University of California, Davis, California, USA.,Global HealthShare Initiative, University of California, Davis, California, USA
| | - Jennifer M Knipe
- Lawrence Livermore National Laboratory, Livermore, California, USA
| |
Collapse
|
2
|
McNulty MJ, Silberstein DZ, Kuhn BT, Padgett HS, Nandi S, McDonald KA, Cross CE. Alpha-1 antitrypsin deficiency and recombinant protein sources with focus on plant sources: Updates, challenges and perspectives. Free Radic Biol Med 2021; 163:10-30. [PMID: 33279618 DOI: 10.1016/j.freeradbiomed.2020.11.030] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 11/20/2020] [Accepted: 11/24/2020] [Indexed: 12/16/2022]
Abstract
Alpha-1 antitrypsin deficiency (A1ATD) is an autosomal recessive disease characterized by low plasma levels of A1AT, a serine protease inhibitor representing the most abundant circulating antiprotease normally present at plasma levels of 1-2 g/L. The dominant clinical manifestations include predispositions to early onset emphysema due to protease/antiprotease imbalance in distal lung parenchyma and liver disease largely due to unsecreted polymerized accumulations of misfolded mutant A1AT within the endoplasmic reticulum of hepatocytes. Since 1987, the only FDA licensed specific therapy for the emphysema component has been infusions of A1AT purified from pooled human plasma at the 2020 cost of up to US $200,000/year with the risk of intermittent shortages. In the past three decades various, potentially less expensive, recombinant forms of human A1AT have reached early stages of development, one of which is just reaching the stage of human clinical trials. The focus of this review is to update strategies for the treatment of the pulmonary component of A1ATD with some focus on perspectives for therapeutic production and regulatory approval of a recombinant product from plants. We review other competitive technologies for treating the lung disease manifestations of A1ATD, highlight strategies for the generation of data potentially helpful for securing FDA Investigational New Drug (IND) approval and present challenges in the selection of clinical trial strategies required for FDA licensing of a New Drug Approval (NDA) for this disease.
Collapse
Affiliation(s)
- Matthew J McNulty
- Department of Chemical Engineering, University of California, Davis, CA, USA
| | - David Z Silberstein
- Department of Chemical Engineering, University of California, Davis, CA, USA
| | - Brooks T Kuhn
- Department of Internal Medicine, University of California, Davis, CA, USA; University of California, Davis, Alpha-1 Deficiency Clinic, Sacramento, CA, USA
| | | | - Somen Nandi
- Department of Chemical Engineering, University of California, Davis, CA, USA; Global HealthShare Initiative®, University of California, Davis, CA, USA
| | - Karen A McDonald
- Department of Chemical Engineering, University of California, Davis, CA, USA; Global HealthShare Initiative®, University of California, Davis, CA, USA
| | - Carroll E Cross
- Department of Internal Medicine, University of California, Davis, CA, USA; University of California, Davis, Alpha-1 Deficiency Clinic, Sacramento, CA, USA; Department of Physiology and Membrane Biology, University of California, Davis, CA, USA.
| |
Collapse
|
3
|
Macharoen K, Du M, Jung S, McDonald KA, Nandi S. Production of recombinant butyrylcholinesterase from transgenic rice cell suspension cultures in a pilot-scale bioreactor. Biotechnol Bioeng 2020; 118:1431-1443. [PMID: 33241854 DOI: 10.1002/bit.27638] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Revised: 11/12/2020] [Accepted: 11/17/2020] [Indexed: 12/17/2022]
Abstract
Producing recombinant proteins in transgenic plant cell suspension cultures in bioreactors provides controllability, reproducibility, scalability, and low-cost production, although low yields remain the major challenge. The studies on scaling-up to pilot-scale bioreactors, especially in conventional stainless-steel stirred tank bioreactors (STB), to produce recombinant proteins in plant cell suspension cultures are very limited. In this study, we scaled-up the production of rice recombinant butyrylcholinesterase (rrBChE), a complex hydrolase enzyme that can be used to prophylactically and therapeutically treat against organophosphorus nerve agents and pesticide exposure, from metabolically regulated transgenic rice cell suspension cultures in a 40-L pilot-scale STB. Employing cyclical operation together with a simplified-process operation (controlling gas sparging rate rather than dissolved oxygen and allowing natural sugar depletion) identified in lab-scale (5 L) bioreactor studies, we found a consistent maximum total active rrBChE production level of 46-58 µg/g fresh weight in four cycles over 82 days of semicontinuous operation. Additionally, maintaining the overall volumetric oxygen mass transfer coefficient (kL a) in the pilot-scale STB to be equivalent to the lab-scale STB improves the maximum total active rrBChE production level and the maximum volumetric productivity to 85 µg/g fresh weight and 387 µg L-1 day-1 , respectively, which are comparable to the lab-scale culture. Here, we demonstrate pilot-scale bioreactor performance using a metabolically regulated transgenic rice cell culture for long-term, reproducible, and sustained production of rrBChE.
Collapse
Affiliation(s)
| | - Min Du
- Department of Chemical Engineering, University of California, Davis, California, USA
| | - Seongwon Jung
- Department of Chemical Engineering, University of California, Davis, California, USA
| | - Karen A McDonald
- Department of Chemical Engineering, University of California, Davis, California, USA.,Global HealthShare® Initiative, University of California, Davis, California, USA
| | - Somen Nandi
- Department of Chemical Engineering, University of California, Davis, California, USA.,Global HealthShare® Initiative, University of California, Davis, California, USA
| |
Collapse
|
4
|
Simplified bioreactor processes for recombinant butyrylcholinesterase production in transgenic rice cell suspension cultures. Biochem Eng J 2020. [DOI: 10.1016/j.bej.2020.107751] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
5
|
Macharoen K, Li Q, Márquez-Escobar VA, Corbin JM, Lebrilla CB, Nandi S, McDonald KA. Effects of Kifunensine on Production and N-Glycosylation Modification of Butyrylcholinesterase in a Transgenic Rice Cell Culture Bioreactor. Int J Mol Sci 2020; 21:ijms21186896. [PMID: 32962231 PMCID: PMC7555773 DOI: 10.3390/ijms21186896] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Revised: 09/18/2020] [Accepted: 09/18/2020] [Indexed: 02/06/2023] Open
Abstract
The production and N-glycosylation of recombinant human butyrylcholinesterase (BChE), a model highly glycosylated therapeutic protein, in a transgenic rice cell suspension culture treated with kifunensine, a strong α-mannosidase I inhibitor, was studied in a 5 L bioreactor. A media exchange was performed at day 7 of cultivation by removing spent sugar-rich medium (NB+S) and adding fresh sugar-free (NB-S) medium to induce the rice α-amylase 3D (RAmy3D) promoter to produce rice recombinant human BChE (rrBChE). Using a 1.25X-concentrated sugar-free medium together with an 80% reduced working volume during the media exchange led to a total active rrBChE production level of 79 ± 2 µg (g FW)-1 or 7.5 ± 0.4 mg L-1 in the presence of kifunensine, which was 1.5-times higher than our previous bioreactor runs using normal sugar-free (NB-S) media with no kifunensine treatment. Importantly, the amount of secreted active rrBChE in culture medium was enhanced in the presence of kifunensine, comprising 44% of the total active rrBChE at day 5 following induction. Coomassie-stained SDS-PAGE gel and Western blot analyses revealed different electrophoretic migration of purified rrBChE bands with and without kifunensine treatment, which was attributed to different N-glycoforms. N-Glycosylation analysis showed substantially increased oligomannose glycans (Man5/6/7/8) in rrBChE treated with kifunensine compared to controls. However, the mass-transfer limitation of kifunensine was likely the major reason for incomplete inhibition of α-mannosidase I in this bioreactor study.
Collapse
Affiliation(s)
- Kantharakorn Macharoen
- Department of Chemical Engineering, University of California, Davis, CA 95616, USA; (K.M.); (V.A.M.-E.); (J.M.C.); (S.N.)
| | - Qiongyu Li
- Department of Chemistry, University of California, Davis, CA 95616, USA; (Q.L.); (C.B.L.)
| | - Veronica A. Márquez-Escobar
- Department of Chemical Engineering, University of California, Davis, CA 95616, USA; (K.M.); (V.A.M.-E.); (J.M.C.); (S.N.)
- Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí 78210, Mexico
- Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí 78210, Mexico
| | - Jasmine M. Corbin
- Department of Chemical Engineering, University of California, Davis, CA 95616, USA; (K.M.); (V.A.M.-E.); (J.M.C.); (S.N.)
| | - Carlito B. Lebrilla
- Department of Chemistry, University of California, Davis, CA 95616, USA; (Q.L.); (C.B.L.)
| | - Somen Nandi
- Department of Chemical Engineering, University of California, Davis, CA 95616, USA; (K.M.); (V.A.M.-E.); (J.M.C.); (S.N.)
- Global HealthShare® Initiative, University of California, Davis, CA 95616, USA
| | - Karen A. McDonald
- Department of Chemical Engineering, University of California, Davis, CA 95616, USA; (K.M.); (V.A.M.-E.); (J.M.C.); (S.N.)
- Global HealthShare® Initiative, University of California, Davis, CA 95616, USA
- Correspondence:
| |
Collapse
|
6
|
Moon KB, Park JS, Park YI, Song IJ, Lee HJ, Cho HS, Jeon JH, Kim HS. Development of Systems for the Production of Plant-Derived Biopharmaceuticals. PLANTS 2019; 9:plants9010030. [PMID: 31878277 PMCID: PMC7020158 DOI: 10.3390/plants9010030] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Revised: 12/20/2019] [Accepted: 12/23/2019] [Indexed: 12/21/2022]
Abstract
Over the last several decades, plants have been developed as a platform for the production of useful recombinant proteins due to a number of advantages, including rapid production and scalability, the ability to produce unique glycoforms, and the intrinsic safety of food crops. The expression methods used to produce target proteins are divided into stable and transient systems depending on applications that use whole plants or minimally processed forms. In the early stages of research, stable expression systems were mostly used; however, in recent years, transient expression systems have been preferred. The production of the plant itself, which produces recombinant proteins, is currently divided into two major approaches, open-field cultivation and closed-indoor systems. The latter encompasses such regimes as greenhouses, vertical farming units, cell bioreactors, and hydroponic systems. Various aspects of each system will be discussed in this review, which focuses mainly on practical examples and commercially feasible approaches.
Collapse
Affiliation(s)
- Ki-Beom Moon
- Plant Systems Engineering Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea; (K.-B.M.); (J.-S.P.); (H.-J.L.); (H.S.C.); (J.-H.J.)
- Department of Biological Sciences, Chungnam National University, 99 Deahank-ro, Yuseong-gu, Daejeon 34134, Korea
| | - Ji-Sun Park
- Plant Systems Engineering Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea; (K.-B.M.); (J.-S.P.); (H.-J.L.); (H.S.C.); (J.-H.J.)
| | - Youn-Il Park
- Department of Biological Sciences, Chungnam National University, 99 Deahank-ro, Yuseong-gu, Daejeon 34134, Korea
| | - In-Ja Song
- National Research Safety Headquarters, Korea Research Institute of Bioscience and Biotechnology, 30 Yeongudanji-ro, Ochang, Chungbuk-do 28116, Korea;
| | - Hyo-Jun Lee
- Plant Systems Engineering Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea; (K.-B.M.); (J.-S.P.); (H.-J.L.); (H.S.C.); (J.-H.J.)
| | - Hye Sun Cho
- Plant Systems Engineering Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea; (K.-B.M.); (J.-S.P.); (H.-J.L.); (H.S.C.); (J.-H.J.)
| | - Jae-Heung Jeon
- Plant Systems Engineering Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea; (K.-B.M.); (J.-S.P.); (H.-J.L.); (H.S.C.); (J.-H.J.)
| | - Hyun-Soon Kim
- Plant Systems Engineering Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea; (K.-B.M.); (J.-S.P.); (H.-J.L.); (H.S.C.); (J.-H.J.)
- Correspondence: ; Tel.: +82-42-860-4493
| |
Collapse
|
7
|
Abstract
Recombinant glycoproteins such as monoclonal antibodies have a major impact on modern healthcare systems, e.g., as the active pharmaceutical ingredients in anticancer drugs. A specific glycan profile is often necessary to achieve certain desirable activities, such as the effector functions of an antibody, receptor binding or a sufficient serum half-life. However, many expression systems produce glycan profiles that differ substantially from the preferred form (usually the form found in humans) or produce a diverse array of glycans with a range of in vivo activities, thus necessitating laborious and costly separation and purification processes. In contrast, protein glycosylation in plant cells is much more homogeneous than other systems, with only one or two dominant forms. Additionally, these glycan profiles tend to remain stable when the process and cultivation conditions are changed, making plant cells an ideal expression system to produce recombinant glycoproteins with uniform glycan profiles in a consistent manner. This chapter describes a protocol that uses fermentations using plant cell cultures to produce glycosylated proteins using two different types of bioreactors, a classical autoclavable STR 3-L and a wave reactor.
Collapse
|
8
|
Abstract
Plant molecular farming depends on a diversity of plant systems for production of useful recombinant proteins. These proteins include protein biopolymers, industrial proteins and enzymes, and therapeutic proteins. Plant production systems include microalgae, cells, hairy roots, moss, and whole plants with both stable and transient expression. Production processes involve a narrowing diversity of bioreactors for cell, hairy root, microalgae, and moss cultivation. For whole plants, both field and automated greenhouse cultivation methods are used with products expressed and produced either in leaves or seeds. Many successful expression systems now exist for a variety of different products with a list of increasingly successful commercialized products. This chapter provides an overview and examples of the current state of plant-based production systems for different types of recombinant proteins.
Collapse
Affiliation(s)
| | - Thomas Bley
- Bioprocess Engineering, Institute of Food Technology and Bioprocess Engineering, TU Dresden, Dresden, Germany
| |
Collapse
|
9
|
Jha S, Agarwal S, Sanyal I, Amla DV. Single-Step Purification and Characterization of A Recombinant Serine Proteinase Inhibitor from Transgenic Plants. Appl Biochem Biotechnol 2016; 179:220-36. [PMID: 26852026 DOI: 10.1007/s12010-016-1989-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Accepted: 01/12/2016] [Indexed: 12/15/2022]
Abstract
Expression of recombinant therapeutic proteins in transgenic plants has a tremendous impact on safe and economical production of biomolecules for biopharmaceutical industry. The major limitation in their production is downstream processing of recombinant protein to obtain higher yield and purity of the final product. In this study, a simple and rapid process has been developed for purification of therapeutic recombinant α1-proteinase inhibitor (rα1-PI) from transgenic tomato plants, which is an abundant serine protease inhibitor in human serum and chiefly inhibits the activity of neutrophil elastase in lungs. We have expressed rα1-PI with modified synthetic gene in transgenic tomato plants at a very high level (≃3.2 % of total soluble protein). The heterologous protein was extracted with (NH4)2SO4 precipitation, followed by chromatographic separation on different matrices. However, only immunoaffinity chromatography resulted into homogenous preparation of rα1-PI with 54 % recovery. The plant-purified rα1-PI showed molecular mass and structural conformation comparable to native serum α1-PI, as shown by mass spectrometry and optical spectroscopy. The results of elastase inhibition assay revealed biological activity of the purified rα1-PI protein. This work demonstrates a simple and efficient one-step purification of rα1-PI from transgenic plants, which is an essential prerequisite for further therapeutic development.
Collapse
Affiliation(s)
- Shweta Jha
- Plant Transgenic Lab, Genetics and Molecular Biology Division, CSIR-National Botanical Research Institute, Rana Pratap Marg, P.O. Box 436, Lucknow, 226001, U.P., India. .,Department of Botany (Centre of Advanced Study), Jai Narain Vyas University, Jodhpur, 342001, India.
| | - Saurabh Agarwal
- Plant Transgenic Lab, Genetics and Molecular Biology Division, CSIR-National Botanical Research Institute, Rana Pratap Marg, P.O. Box 436, Lucknow, 226001, U.P., India.,Baylor College of Medicine, Houston, TX, USA
| | - Indraneel Sanyal
- Plant Transgenic Lab, Genetics and Molecular Biology Division, CSIR-National Botanical Research Institute, Rana Pratap Marg, P.O. Box 436, Lucknow, 226001, U.P., India
| | - D V Amla
- Plant Transgenic Lab, Genetics and Molecular Biology Division, CSIR-National Botanical Research Institute, Rana Pratap Marg, P.O. Box 436, Lucknow, 226001, U.P., India
| |
Collapse
|
10
|
Santos RB, Abranches R, Fischer R, Sack M, Holland T. Putting the Spotlight Back on Plant Suspension Cultures. FRONTIERS IN PLANT SCIENCE 2016; 7:297. [PMID: 27014320 PMCID: PMC4786539 DOI: 10.3389/fpls.2016.00297] [Citation(s) in RCA: 91] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Accepted: 02/25/2016] [Indexed: 05/05/2023]
Abstract
Plant cell suspension cultures have several advantages that make them suitable for the production of recombinant proteins. They can be cultivated under aseptic conditions using classical fermentation technology, they are easy to scale-up for manufacturing, and the regulatory requirements are similar to those established for well-characterized production systems based on microbial and mammalian cells. It is therefore no surprise that taliglucerase alfa (Elelyso®)-the first licensed recombinant pharmaceutical protein derived from plants-is produced in plant cell suspension cultures. But despite this breakthrough, plant cells are still largely neglected compared to transgenic plants and the more recent plant-based transient expression systems. Here, we revisit plant cell suspension cultures and highlight recent developments in the field that show how the rise of plant cells parallels that of Chinese hamster ovary cells, currently the most widespread and successful manufacturing platform for biologics. These developments include medium optimization, process engineering, statistical experimental designs, scale-up/scale-down models, and process analytical technologies. Significant yield increases for diverse target proteins will encourage a gold rush to adopt plant cells as a platform technology, and the first indications of this breakthrough are already on the horizon.
Collapse
Affiliation(s)
- Rita B. Santos
- Plant Cell Biology Laboratory, Universidade Nova de Lisboa, Instituto de Tecnologia Química e Biológica António XavierOeiras, Portugal
| | - Rita Abranches
- Plant Cell Biology Laboratory, Universidade Nova de Lisboa, Instituto de Tecnologia Química e Biológica António XavierOeiras, Portugal
| | - Rainer Fischer
- Fraunhofer-Institut für Molekularbiologie und Angewandte Oekologie (IME), Integrated Production PlatformsAachen, Germany
- Biology VII, Institute for Molecular Biotechnology, RWTH Aachen UniversityAachen, Germany
| | - Markus Sack
- Biology VII, Institute for Molecular Biotechnology, RWTH Aachen UniversityAachen, Germany
| | - Tanja Holland
- Fraunhofer-Institut für Molekularbiologie und Angewandte Oekologie (IME), Integrated Production PlatformsAachen, Germany
- *Correspondence: Tanja Holland
| |
Collapse
|
11
|
Corbin JM, Hashimoto BI, Karuppanan K, Kyser ZR, Wu L, Roberts BA, Noe AR, Rodriguez RL, McDonald KA, Nandi S. Semicontinuous Bioreactor Production of Recombinant Butyrylcholinesterase in Transgenic Rice Cell Suspension Cultures. FRONTIERS IN PLANT SCIENCE 2016; 7:412. [PMID: 27066048 PMCID: PMC4814504 DOI: 10.3389/fpls.2016.00412] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2015] [Accepted: 03/17/2016] [Indexed: 05/17/2023]
Abstract
An active and tetrameric form of recombinant butyrylcholinesterase (BChE), a large and complex human enzyme, was produced via semicontinuous operation in a transgenic rice cell suspension culture. After transformation of rice callus and screening of transformants, the cultures were scaled up from culture flask to a lab scale bioreactor. The bioreactor was operated through two phases each of growth and expression. The cells were able to produce BChE during both expression phases, with a maximum yield of 1.6 mg BChE/L of culture during the second expression phase. Cells successfully regrew during a 5-day growth phase. A combination of activity assays and Western blot analysis indicated production of an active and fully assembled tetramer of BChE.
Collapse
Affiliation(s)
- Jasmine M. Corbin
- Chemical Engineering and Materials Science, University of California, DavisDavis, CA, USA
| | - Bryce I. Hashimoto
- Chemical Engineering and Materials Science, University of California, DavisDavis, CA, USA
| | - Kalimuthu Karuppanan
- Chemical Engineering and Materials Science, University of California, DavisDavis, CA, USA
| | - Zachary R. Kyser
- Chemical Engineering and Materials Science, University of California, DavisDavis, CA, USA
| | | | | | | | - Raymond L. Rodriguez
- Global HealthShare®, Molecular and Cellular Biology, University of California, DavisDavis, CA, USA
| | - Karen A. McDonald
- Chemical Engineering and Materials Science, University of California, DavisDavis, CA, USA
| | - Somen Nandi
- Global HealthShare®, Molecular and Cellular Biology, University of California, DavisDavis, CA, USA
- *Correspondence: Somen Nandi
| |
Collapse
|
12
|
On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect. ACTA ACUST UNITED AC 2014; 2:499-518. [PMID: 25621170 DOI: 10.4155/pbp.14.32] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Plant cell culture is emerging as an alternative bioproduction system for recombinant pharmaceuticals. Growing plant cells in vitro under controlled environmental conditions allows for precise control over cell growth and protein production, batch-to-batch product consistency and a production process aligned with current good manufacturing practices. With the recent US FDA approval and commercialization of the world's first plant cell-based recombinant pharmaceutical for human use, β-glucocerebrosidase for treatment of Gaucher's disease, a new era has come in which plant cell culture shows high potential to displace some established platform technologies in niche markets. This review updates the progress in plant cell culture processing technology, highlights recent commercial successes and discusses the challenges that must be overcome to make this platform commercially viable.
Collapse
|
13
|
Green factory: Plants as bioproduction platforms for recombinant proteins. Biotechnol Adv 2012; 30:1171-84. [DOI: 10.1016/j.biotechadv.2011.08.020] [Citation(s) in RCA: 132] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2011] [Revised: 08/24/2011] [Accepted: 08/30/2011] [Indexed: 12/15/2022]
|
14
|
Huang TK, McDonald KA. Bioreactor systems for in vitro production of foreign proteins using plant cell cultures. Biotechnol Adv 2011; 30:398-409. [PMID: 21846499 DOI: 10.1016/j.biotechadv.2011.07.016] [Citation(s) in RCA: 74] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2011] [Revised: 06/17/2011] [Accepted: 07/25/2011] [Indexed: 12/31/2022]
Abstract
Plant cells have been demonstrated to be an attractive heterologous expression host (using whole plants and in vitro plant cell cultures) for foreign protein production in the past 20years. In recent years in vitro liquid cultures of plant cells in a fully contained bioreactor have become promising alternatives to traditional microbial fermentation and mammalian cell cultures as a foreign protein expression platform, due to the unique features of plant cells as a production host including product safety, cost-effective biomanufacturing, and the capacity for complex protein post-translational modifications. Heterologous proteins such as therapeutics, antibodies, vaccines and enzymes for pharmaceutical and industrial applications have been successfully expressed in plant cell culture-based bioreactor systems including suspended dedifferentiated plant cells, moss, and hairy roots, etc. In this article, the current status and emerging trends of plant cell culture for in vitro production of foreign proteins will be discussed with emphasis on the technological progress that has been made in plant cell culture bioreactor systems.
Collapse
Affiliation(s)
- Ting-Kuo Huang
- Department of Chemical Engineering and Materials Science, University of California, Davis, CA 95616, United States
| | | |
Collapse
|
15
|
Xu J, Ge X, Dolan MC. Towards high-yield production of pharmaceutical proteins with plant cell suspension cultures. Biotechnol Adv 2011; 29:278-99. [DOI: 10.1016/j.biotechadv.2011.01.002] [Citation(s) in RCA: 137] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2010] [Revised: 12/24/2010] [Accepted: 01/02/2011] [Indexed: 12/16/2022]
|
16
|
Huang TK, Plesha MA, McDonald KA. Semicontinuous bioreactor production of a recombinant human therapeutic protein using a chemically inducible viral amplicon expression system in transgenic plant cell suspension cultures. Biotechnol Bioeng 2010; 106:408-21. [PMID: 20198659 DOI: 10.1002/bit.22713] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Plant cell culture is an alternative for the production of recombinant human therapeutic proteins because of improved product safety, lower production cost, and capability for eukaryotic post-translational modification. In this study, bioreactor production of recombinant human alpha-1-antitrypsin (rAAT) glycoprotein using a chemically inducible Cucumber mosaic virus (CMV) viral amplicon expression system in transgenic Nicotiana benthamiana cell culture is presented. Optimization of a chemically inducible plant cell culture requires evaluation of effects of timing of induction (TOI) and concentration of inducer (COI) on protein productivity and protein quality (biological functionality). To determine the optimal TOI, the oxygen uptake rate (OUR) of the plant cell culture was chosen as a physiological indicator for inducing maximum rAAT expression. Effects of COI on rAAT production were investigated using a semicontinuous culture, which enables the distinction between effects of growth rate and effects of inducer concentration. An optimized semicontinuous bioreactor operation was further proposed to maximize the recombinant protein production. The results demonstrated that the transgenic plant cells, transformed with the inducible viral amplicon expression system, maintain higher OUR and exhibit lower extracellular protease activity and lower total phenolics concentration in the optimized semicontinuous bioreactor process than in a traditional batch bioreactor operation, resulting in a 25-fold increase in extracellular functional rAAT (603 microg/L) and a higher ratio of functional rAAT to total rAAT (85-90%). Surprisingly, sustained rAAT production and steady state, long-term bioreactor operation is possible following chemical induction and establishment of the viral amplicons.
Collapse
Affiliation(s)
- Ting-Kuo Huang
- Department of Chemical Engineering and Materials Science, University of California at Davis, 95616, USA
| | | | | |
Collapse
|
17
|
Kwon JY, Cheon SH, Lee HR, Han JY, Kim DI. Production of biopharmaceuticals in transgenic plant cell suspension cultures. ACTA ACUST UNITED AC 2009. [DOI: 10.5010/jpb.2009.36.4.309] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Huang TK, McDonald KA. Bioreactor engineering for recombinant protein production in plant cell suspension cultures. Biochem Eng J 2009. [DOI: 10.1016/j.bej.2009.02.008] [Citation(s) in RCA: 114] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
19
|
Huang TK, Plesha MA, Falk BW, Dandekar AM, McDonald KA. Bioreactor strategies for improving production yield and functionality of a recombinant human protein in transgenic tobacco cell cultures. Biotechnol Bioeng 2009; 102:508-20. [PMID: 18767186 DOI: 10.1002/bit.22061] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Plant cell culture production of recombinant products offers a number of advantages over traditional eukaryotic expression systems, particularly if the product can be targeted to and purified from the cell culture broth. However, one of the main obstacles is product degradation by proteases that are produced during cell culture, and/or the loss of biological activity of secreted (extracellular) products as a result of alteration in the protein conformation. Because proteolysis activity and target protein stability can be significantly influenced by culture conditions, it is important to evaluate bioprocess conditions that minimize these effects. In this study, a bioreactor strategy using a protocol involving pH adjustment and medium exchange during plant cell culture is proposed for improving the production of functional recombinant alpha(1)-antitrypsin (rAAT), a human blood protein, produced using several alternative expression systems, including a Cauliflower mosaic virus (CaMV) 35S constitutive promoter expression system, a chemically inducible, estrogen receptor-based promoter (XVE) expression system, and a novel Cucumber mosaic virus (CMV) inducible viral amplicon (CMViva) expression system developed by our group. We have demonstrated that higher medium pH help reduce protease activity derived from cell cultures and improve the inherent stability of human AAT protein as well. This strategy resulted in a fourfold increase in the productivity of extracellular functional rAAT (100 microg/L) and a twofold increase in the ratio of functional rAAT to total rAAT (48%) in transgenic N. benthamiana cell cultures using a chemically inducible viral amplicon expression system.
Collapse
Affiliation(s)
- Ting-Kuo Huang
- Department of Chemical Engineering and Materials Science, University of California, Davis, 1 Shields Avenue, Davis, California 95616, USA
| | | | | | | | | |
Collapse
|
20
|
Agarwal S, Singh R, Sanyal I, Amla DV. Expression of modified gene encoding functional human alpha-1-antitrypsin protein in transgenic tomato plants. Transgenic Res 2008; 17:881-96. [PMID: 18320339 DOI: 10.1007/s11248-008-9173-8] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2007] [Accepted: 02/08/2008] [Indexed: 10/22/2022]
Abstract
Transgenic plants offer promising alternative for large scale, sustainable production of safe, functional, recombinant proteins of therapeutic and industrial importance. Here, we report the expression of biologically active human alpha-1-antitrypsin in transgenic tomato plants. The 1,182 bp cDNA sequence of human AAT was strategically designed, modified and synthesized to adopt codon usage pattern of dicot plants, elimination of mRNA destabilizing sequences and modifications around 5' and 3' flanking regions of the gene to achieve high-level regulated expression in dicot plants. The native signal peptide sequence was substituted with modified signal peptide sequence of tobacco (Nicotiana tabacum) pathogenesis related protein PR1a, sweet potato (Ipomoea batatas) sporamineA and with dicot-preferred native signal peptide sequence of AAT gene. A dicot preferred translation initiation context sequence, 38 bp alfalfa mosaic virus untranslated region were incorporated at 5' while an endoplasmic reticulum retention signal (KDEL) was incorporated at 3' end of the gene. The modified gene was synthesized by PCR based method using overlapping oligonucleotides. Tomato plants were genetically engineered by nuclear transformation with Agrobacterium tumefaciens harbouring three different constructs pPAK, pSAK and pNAK having modified AAT gene with different signal peptide sequences under the control of CaMV35S duplicated enhancer promoter. Promising transgenic plants expressing recombinant AAT protein upto 1.55% of total soluble leaf protein has been developed and characterized. Plant-expressed recombinant AAT protein with molecular mass of around approximately 50 kDa was biologically active, showing high specific activity and efficient inhibition of elastase activity. The enzymatic deglycosylation established proper glycosylation of the plant-expressed recombinant AAT protein in contrast to unglycosylated rAAT expressed in E. coli ( approximately 45 kDa). Our results demonstrate feasibility for high-level expression of biologically active, glycosylated human alpha-1-antitrypsin in transgenic tomato plants.
Collapse
Affiliation(s)
- Saurabh Agarwal
- Plant Transgenic Lab, National Botanical Research Institute, PO Box 436, Rana Pratap Marg, Lucknow, 226001, India
| | | | | | | |
Collapse
|
21
|
Comparative proteomic analysis for hCTLA4Ig production in transgenic rice suspension cultures using two-dimensional difference gel electrophoresis. BIOTECHNOL BIOPROC E 2007. [DOI: 10.1007/bf02931053] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
22
|
Boehm R. Bioproduction of therapeutic proteins in the 21st century and the role of plants and plant cells as production platforms. Ann N Y Acad Sci 2007; 1102:121-34. [PMID: 17470916 PMCID: PMC7168112 DOI: 10.1196/annals.1408.009] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
abstract: In the last decade, the technique to genetically modify crop plants has gained more and more interest in terms of bioproduction of heterologous proteins. Plants have been discovered as a possible source for large amounts of cost effective recombinant protein. Main application fields are therapeutics for use in animal and human health, diagnostics, and technical enzymes. This review is focused on the recent progress in this field of molecular farming. After a comparison with hitherto established protein production systems, the advantages of plants as an alternative production system are discussed. An overview about the different host plants and possible expression strategies is given and the progress in commercialization of the techniques is highlighted. Finally, the role of plant cell cultures for the production of recombinant proteins is discussed.
Collapse
Affiliation(s)
- Robert Boehm
- Institute of Plant Molecular Physiology and Biotechnology, Karlrobert Kreiten-Str 13, Bonn, University of Bonn, Germany.
| |
Collapse
|
23
|
Cho JS, Hong SM, Joo SY, Yoo JS, Kim DI. Cryopreservation of transgenic rice suspension cells producing recombinant hCTLA4Ig. Appl Microbiol Biotechnol 2006; 73:1470-6. [PMID: 17021872 DOI: 10.1007/s00253-006-0627-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2006] [Revised: 08/07/2006] [Accepted: 08/09/2006] [Indexed: 10/24/2022]
Abstract
Transgenic suspension cells of Oryza sativa L. cv. Dongjin utilized as a host for producing recombinant human cytotoxic T-lymphocyte antigen 4-immunoglobulin (hCTLA4Ig) were preserved in liquid nitrogen (-196 degrees C) after slow prefreezing in a deep freezer (-70 degrees C). The development of an optimal procedure for long-term storage was investigated by the addition of various concentrations of cryoprotectant mixture and osmoticum in preculture media before cooling. A pre-deep-freezing time of 120 min was the most effective for maintaining cell viability. Compared with mannitol, sorbitol, trehalose, and NaCl under the same osmotic conditions, 0.5 M sucrose was found to be the best osmoticum for preculture media. The cryoprotectant comprising sucrose, glycerol, and dimethylsulfoxide (DMSO) was applied to the precultured cells, and a combination of 1 M sucrose, 1 M glycerol, and 1 M DMSO provided the best result. The viability with this optimized condition was 88% after cryocell-banking for 1 day. The expression of hCTLA4Ig in recovered callus from cryopreservation was also kept stable, and the production level was similar to that observed in noncryopreserved cultures.
Collapse
Affiliation(s)
- Ji-Suk Cho
- Department of Biological Engineering, Inha University, Incheon, 402-751, Republic of Korea
| | | | | | | | | |
Collapse
|
24
|
Sudarshana MR, Plesha MA, Uratsu SL, Falk BW, Dandekar AM, Huang TK, McDonald KA. A chemically inducible cucumber mosaic virus amplicon system for expression of heterologous proteins in plant tissues. PLANT BIOTECHNOLOGY JOURNAL 2006; 4:551-9. [PMID: 17309729 DOI: 10.1111/j.1467-7652.2006.00202.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
A novel cucumber mosaic virus inducible viral amplicon (CMViva) expression system has been developed that allows for tightly regulated chemically inducible expression of heterologous genes in plant hosts. Transient production of recombinant alpha(1)-antitrypsin (rAAT), a human blood protein, was demonstrated in Nicotiana benthamiana leaves. The highest production levels were obtained by co-infiltrating leaves with Agrobacterium tumefaciens cells containing CMViva carrying the AAT gene and A. tumefaciens cells carrying a binary vector constitutively expressing the gene silencing suppressor p19. Accumulation of up to thirty-fold more rAAT was observed in leaves (24 mg per 100 g leaf tissue) when compared with the expression levels observed using the cauliflower mosaic virus (CaMV) 35S promoter. Significantly, 70% of the rAAT produced using the CMViva expression system was found to be biologically active, a 170-fold increase in functional protein compared with the CaMV 35S expression system.
Collapse
Affiliation(s)
- Mysore R Sudarshana
- Department of Plant Pathology, University of California at Davis, One Shields Ave., Davis, CA 95616, USA
| | | | | | | | | | | | | |
Collapse
|
25
|
Doran PM. Foreign protein degradation and instability in plants and plant tissue cultures. Trends Biotechnol 2006; 24:426-32. [PMID: 16843560 DOI: 10.1016/j.tibtech.2006.06.012] [Citation(s) in RCA: 157] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2005] [Accepted: 06/29/2006] [Indexed: 11/27/2022]
Abstract
Low production cost is a key factor driving the development of plants and plant tissue cultures for the synthesis of therapeutic and other foreign proteins. Because product yield and concentration exert a major influence on process economics, improving foreign protein accumulation is crucial for enhancing the commercial success of plant-based production systems. Strategies aimed at increasing transgene expression have been effective; however, a critical but poorly understood factor contributing to low foreign protein yield is post-synthesis and/or post-secretion instability and degradation. Loss of foreign protein as result of biological and physical processes such as proteolytic destruction and irreversible surface adsorption can occur in plants and plant culture systems. This review highlights the need to consider such mechanisms and outlines a range of remedial strategies aimed at minimizing foreign protein degradation and loss.
Collapse
Affiliation(s)
- Pauline M Doran
- School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
| |
Collapse
|
26
|
McDonald KA, Hong LM, Trombly DM, Xie Q, Jackman AP. Production of human alpha-1-antitrypsin from transgenic rice cell culture in a membrane bioreactor. Biotechnol Prog 2005; 21:728-34. [PMID: 15932249 DOI: 10.1021/bp0496676] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Transgenic plant cell cultures offer a number of advantages over alternative host expression systems, but so far relatively low product concentrations have been achieved. In this study, transgenic rice cells are used in a two-compartment membrane bioreactor (CELLine 350, Integra Biosciences) for the production of recombinant alpha-1-antitrypsin (rAAT). Expression of rAAT is controlled by the rice alpha-amylase (RAmy3D) promoter, which is induced in the absence of sugar. The extracellular product is retained in the bioreactor's relatively small cell compartment, thereby increasing product concentration. Due to the packed nature of the cell aggregates in the cell compartment, a clarified product solution can be withdrawn from the bioreactor. Active rAAT reached levels of 100-247 mg/L (4-10% of the total extracellular protein) in the cell compartment at 5-6 days postinduction, and multiple inductions of the RAmy3D promoter were demonstrated.
Collapse
Affiliation(s)
- Karen A McDonald
- Department of Chemical Engineering and Materials Science, University of California at Davis, One Shields Avenue, Davis, California 95616, USA.
| | | | | | | | | |
Collapse
|